December 9, 2016 / 11:43 AM / 7 months ago

BRIEF-Eli lilly says Solanezumab did not meet primary endpoint in expedition3 clinical trial

1 Min Read

Dec 9 (Reuters) - Eli Lilly And Co

* Will not pursue regulatory submissions for Solanezumab for treatment of mild dementia due to AD

* Solanezumab did not meet primary endpoint in expedition3 clinical trial

* Lilly announces detailed results of solanezumab phase 3 expedition3 study at the clinical trials on alzheimer's disease (CTAD) 2016 meeting Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below